Moderna and Merck Team Up for Cancer Trial with mRNA Vaccine and Checkpoint Inhibitor

Moderna and Merck are collaborating on a cancer trial, according to an announcement from The Gazette. The two pharmaceutical companies have partnered up for a clinical trial that aims to assess the effectiveness of their joint treatment in fighting certain types of cancer.

The trial is expected to enroll patients with non-small cell lung cancer (NSCLC) and will involve testing the efficacy of a combination therapy that includes Moderna's mRNA-4157 vaccine, along with Merck's checkpoint inhibitor.

According to The Gazette, Moderna and Merck believe their combined approach may offer a new and promising treatment option for patients with NSCLC. However, no further details about the trial's design or expected timeline were provided in the announcement.